%0 Journal Article
%A Riggioni, Carmen
%A Comberiati, Pasquale
%A Giovannini, Mattia
%A Agache, Ioana
%A Akdis, Mübeccel
%A Alves-Correia, Magna
%A Antó, Josep M
%A Arcolaci, Alessandra
%A Azkur, Ahmet Kursat
%A Azkur, Dilek
%A Beken, Burcin
%A Boccabella, Cristina
%A Bousquet, Jean
%A Breiteneder, Heimo
%A Carvalho, Daniela
%A De Las Vecillas, Leticia
%A Diamant, Zuzana
%A Eguiluz-Gracia, Ibon
%A Eiwegger, Thomas
%A Eyerich, Stefanie
%A Fokkens, Wytske
%A Gao, Ya-Dong
%A Hannachi, Farah
%A Johnston, Sebastian L
%A Jutel, Marek
%A Karavelia, Aspasia
%A Klimek, Ludger
%A Moya, Beatriz
%A Nadeau, Kari C
%A O'Hehir, Robyn
%A O'Mahony, Liam
%A Pfaar, Oliver
%A Sanak, Marek
%A Schwarze, Jürgen
%A Sokolowska, Milena
%A Torres, María J
%A van de Veen, Willem
%A van Zelm, Menno C
%A Wang, De Yun
%A Zhang, Luo
%A Jiménez-Saiz, Rodrigo
%A Akdis, Cezmi A
%T A compendium answering 150 questions on COVID-19 and SARS-CoV-2.
%D 2020
%U http://hdl.handle.net/10668/15736
%X In December 2019, China reported the first cases of the coronavirus disease 2019 (COVID-19). This disease, caused by the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), has developed into a pandemic. To date, it has resulted in ~9 million confirmed cases and caused almost 500 000 related deaths worldwide. Unequivocally, the COVID-19 pandemic is the gravest health and socioeconomic crisis of our time. In this context, numerous questions have emerged in demand of basic scientific information and evidence-based medical advice on SARS-CoV-2 and COVID-19. Although the majority of the patients show a very mild, self-limiting viral respiratory disease, many clinical manifestations in severe patients are unique to COVID-19, such as severe lymphopenia and eosinopenia, extensive pneumonia, a "cytokine storm" leading to acute respiratory distress syndrome, endothelitis, thromboembolic complications, and multiorgan failure. The epidemiologic features of COVID-19 are distinctive and have changed throughout the pandemic. Vaccine and drug development studies and clinical trials are rapidly growing at an unprecedented speed. However, basic and clinical research on COVID-19-related topics should be based on more coordinated high-quality studies. This paper answers pressing questions, formulated by young clinicians and scientists, on SARS-CoV-2, COVID-19, and allergy, focusing on the following topics: virology, immunology, diagnosis, management of patients with allergic disease and asthma, treatment, clinical trials, drug discovery, vaccine development, and epidemiology. A total of 150 questions were answered by experts in the field providing a comprehensive and practical overview of COVID-19 and allergic disease.
%K COVID-19
%K SARS-CoV-2
%K allergy
%K coronavirus disease 2019
%K severe acute respiratory syndrome-related coronavirus 2
%~